Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Surgical Anastomosis
100%
Recurrent Disease
94%
Retroperitoneal Sarcoma
92%
Gastric Bypass Surgery
90%
Gastric Bypass
90%
Diseases
83%
Sleeve Gastrectomy
80%
Overall Survival
77%
Neoplasm
73%
Soft Tissue Sarcoma
73%
Morbidity
67%
Body Mass Index
58%
Tumor
58%
Connective Tissue Cancer
57%
Bariatric Surgery
54%
Long-Term Outcome
53%
Postoperative Complication
47%
Lymph Node
45%
Lymph Node Metastasis
39%
Hyperthermic Intraperitoneal Chemotherapy
37%
Pancreas Adenocarcinoma
36%
Elderly Patient
35%
Intraperitoneal Chemotherapy
35%
Peritoneum Metastasis
34%
Tissue Microarray
33%
Pancreas Cancer
33%
Cytoreductive Surgery
31%
Liposarcoma
30%
Crohn's Disease
30%
Cancer
29%
Abdominal Wall
28%
Laparoscopic Sleeve Gastrectomy
28%
Angiosarcoma
28%
Obesity Medicine
28%
Metastatic Carcinoma
27%
Chemotherapy
26%
Histology
24%
Surgical Oncology
24%
Reoperation
24%
Surgeon
23%
Disease Free Survival
22%
Digestive System Surgery
21%
Pancreas Islet Cell Tumor
21%
Roux-en-Y Gastric Bypass
20%
Cholecystectomy
20%
Abdominal Wall Hernia
19%
Disease Specific Survival
19%
Malignant Neoplasm
19%
Ventral Hernia Repair
18%
Prognostic Factor
18%
Keyphrases
Soft Tissue Sarcoma
89%
Retroperitoneal Sarcoma
85%
Sleeve Gastrectomy
83%
One-anastomosis Gastric Bypass
68%
Bariatric Surgery
60%
Overall Survival
58%
Resection
54%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
51%
Tumor
50%
Metabolic Surgery
47%
Body Mass Index
42%
Crohn's Disease
36%
Laparoscopic Sleeve Gastrectomy
35%
Elderly Patients
35%
Peritoneal Metastasis
34%
Patient Outcomes
34%
Postoperative Outcomes
32%
Cytoreductive Surgery
31%
Postoperative Complications
29%
Retrospective Analysis
28%
Tertiary Care Centers
28%
Chemotherapy
27%
Postoperative Morbidity
27%
Bariatric
27%
Lymph Node Metastasis
26%
Local Recurrence
26%
Lymph Node Ratio
25%
Sarcoma
24%
Pancreatic Ductal Adenocarcinoma
24%
Tissue Microarray
23%
Roux-en-Y Gastric Bypass
22%
Retroperitoneal Liposarcoma
22%
Total Weight Loss
22%
Multivariable
21%
Well-differentiated
21%
Angiosarcoma
21%
FOLFIRINOX
21%
Neoadjuvant
21%
Borderline Resectable Pancreatic Cancer
21%
Sarcoma Cells
21%
Prognosticator
21%
Abdominal Wall Reconstruction
20%
Dedifferentiated
20%
Disease-specific Survival
19%
Revisional
18%
Medical Center
18%
Reoperation
17%
Pancreaticoduodenectomy
17%
Metastasis
17%
Ventral Hernia Repair
17%